Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

Inclusion Criteria: * Age ≤ 25 years old at the time of inclusion in the study * Patient with a pediatric tumor or leukemia in therapeutic failure or relapse without standard therapeutic options. Exceptionally, patients on the first line of treatment without standard therapeutic options may also be included (eg g: inoperable plexiform neurofibroma and MEK inhibitors, childhood fibrosarcoma and NTRK inhibitors). * Patient not eligible for an early phase clinical trial open to inclusion on French territory or refusal of inclusion * Patient treated with a new drug discussed at a RCPPI as part of a compassionate use issued by the ANSM or an off-label prescription of a drug of interest already authorized in adults. * Patients treated in one of the SFCE centers authorized to prescribe chemotherapy * Patient who did not object to participate after being informed of the study. The patient must be able and willing to cooperate in the study. Exclusion Criteria: * Patient included in an early phase clinical trial open to inclusions on French territory. * Oral refusal to participate by the patient or their legal representatives, in reading the information note specific to the study * Patient under guardianship or curatorship, deprived of liberty or in the impossibility of expressing opposition to participating in the study